Acellera’s Collaborations Clause Samples

Acellera’s Collaborations. Since the beginning of the project, Acellera participated in the dissemination of the project news and promoted the use of in silico methods in industry and non-profit entities by participating and organising events, but especially by its effective marketing activity (during national and international events, such as congresses, and through their channels of digital marketing, such as Acellera website, LinkedIn and Twitter). This activity is illustrated by the organisation of workshops, its participation in workshops and its participation in various events and webinar (see Section 6.1.3). Acellera’s ISBA protocol has been optimized and is ready to initiate collaboration among CompBioMed partners. Discussions with CompBioMed partners ▇▇▇▇▇▇ and ▇▇▇▇▇▇▇ were started to define the systems to study, the approach to consider, and the legal aspects when sharing technological or scientific knowledge among partners. Since simulations depend on the choice of molecule, emphasis has been put on the development of the protocol, particularly the sampling protocol (e.g.: Adaptive sampling, Adaptive Goal sampling) and its deployment to scale-up the simulations (clusters and Cloud). Today, these protocols are implemented in the software provided by Acellera and used both for services and internal research projects at Acellera. They demonstrated their robustness when predicting ligand binding site and reproducing the binding pathway and have proved to be applicable to a wide range of biomolecules. Moreover, Acellera provides free access through its platform ▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ to promote the use of in silico methods for drug discovery and molecular medicine projects (see statistics shared elsewhere). This platform encountered a large success since its release in June 2017. Between June 2017 and March 2019, the number of visits reached 16000 distributed including some 85% of non-profit entities’ users and 15% of industrial users, not only from large pharmaceutical companies but also SMEs. Several contacts were established with both large pharmaceutical companies and SMEs, showing a clear interest for the platform but also demonstrating the potential of the platform for visibility, testing and validating the interest for new applications or software in biomedicine. In order to propose a larger offering and more power for Cloud Computing, Acellera contacted CompBioMed’s Associate Partner Microsoft Azure. A recent (December 2018) collaboration has been set in order to promote Ace...